Tyra Biosciences (TYRA) Dabogratinib Delivers 57% Complete Response Rate in Phase 2 Trial. Is Phase 3 Supported?

Tyra Biosciences (TYRA) reported Phase 2 trial results for dabogratinib, showing a 57% complete response rate in patients with FGFR3-altered bladder cancer. The study met its primary endpoint, with 79% objective response rate. The company plans further enrollment and regulatory discussions for Phase 3 design. Safety data showed no severe adverse events at the 60 mg dose.

Original reporting
Published Sep 16, 2026, 9:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 9:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Tyra Biosciences (TYRA) Dabogratinib Delivers 57% Complete Response Rate in Phase 2 Trial. Is Phase 3 Supported? — source image
Decision brief

The 30-second read

$TYRABullishMed
01

Why it matters

The 57% complete response rate may catalyze a re‑rating of the stock and influence investor sentiment toward similar biotech pipelines.

02

Market read

First‑time disclosure of promising Phase 2 data provides fresh trading catalyst for TYRA and related oncology biotech stocks.

03

What to watch

Potential regulatory hurdles and competition from other FGFR inhibitors not discussed.

Relevance 8/10Novelty 8/10Timing: today

Background

Tyra Biosciences disclosed its first Phase 2 results for dabogratinib in FGFR3‑altered bladder cancer.

Company-level read

Ticker impact

$TYRABullishMedium confidence
Context

Phase 2 SURF302 trial reported 57% complete response rate for dabogratinib.

Expected impact

Potential upside if data spurs investor optimism ahead of Phase 3 design.

Evidence & confidence

Data is encouraging but limited sample size; market may price in upside while awaiting larger trials.

Market effects

Boosts confidence in FGFR3‑targeted therapies and may lift peer biotech stocks.

Limited to US biotech sector; no broader regional effect.

Modest, confined to oncology drug development community.

Counterpoint

Small sample and open‑label design could overstate efficacy; risk of disappointment in Phase 3.

Key entities

  • Tyra Biosciences, Inc.

    US‑listed biotech developing FGFR3 inhibitors.

Related articles

$TYRAMed

Tyra Biosciences 3Q 2026: EPS ($0.74) — 10-Q Summary

Tyra Biosciences reported a wider net loss in 3Q 2026, with R&D costs rising due to dabogratinib trials and headcount growth. Net loss was $51.12M, and diluted EPS was ($0.74). The company has $700.5M in cash, expected to last through 2030. Dabogratinib trials showed initial positive results.

$TYRAHighAI 8/10

Raymond James reiterates Strong Buy on Tyra Biosciences stock

Raymond James reiterated a Strong Buy rating and $50 price target for Tyra Biosciences (NASDAQ:TYRA) after a discussion with its CEO. The stock trades at $20.93, with analyst targets ranging from $29 to $59. Tyra's lead asset, dabogratinib, showed promising Phase 2 data for non-muscle invasive bladder cancer, with a 100% overall response rate at a 60 mg dose. Raymond James projects $2 billion in combined revenue by 2035 from Tyra's three opportunities.